Boit C F David Takes Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Boit C F David purchased a new stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,250 shares of the company’s stock, valued at approximately $102,000.

Several other large investors have also modified their holdings of GEHC. Sanders Morris Harris LLC acquired a new position in GE HealthCare Technologies during the 2nd quarter worth about $201,000. Bard Financial Services Inc. acquired a new position in GE HealthCare Technologies during the 2nd quarter worth about $598,000. Maryland State Retirement & Pension System acquired a new position in GE HealthCare Technologies during the 2nd quarter worth about $2,419,000. Finally, Czech National Bank acquired a new position in GE HealthCare Technologies during the 2nd quarter worth about $3,750,000. Institutional investors and hedge funds own 79.18% of the company’s stock.

Insider Buying and Selling

In related news, CEO Kevin Michael O’neill sold 15,609 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $77.32, for a total transaction of $1,206,887.88. Following the transaction, the chief executive officer now owns 24,025 shares in the company, valued at approximately $1,857,613. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.21% of the stock is currently owned by company insiders.

GE HealthCare Technologies Stock Performance

GEHC opened at $66.43 on Friday. GE HealthCare Technologies Inc. has a one year low of $53.00 and a one year high of $87.83. The company has a current ratio of 1.22, a quick ratio of 0.92 and a debt-to-equity ratio of 1.44. The business’s 50-day simple moving average is $73.37 and its 200-day simple moving average is $77.06.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Tuesday, July 25th. The company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $0.05. The business had revenue of $4.82 billion during the quarter, compared to analysts’ expectations of $4.79 billion. The company’s quarterly revenue was up 7.4% on a year-over-year basis. As a group, analysts forecast that GE HealthCare Technologies Inc. will post 3.8 earnings per share for the current year.

GE HealthCare Technologies Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, August 15th. Investors of record on Friday, July 21st were paid a dividend of $0.03 per share. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $0.12 dividend on an annualized basis and a yield of 0.18%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Argus assumed coverage on GE HealthCare Technologies in a research report on Friday, August 25th. They issued a “buy” rating and a $80.00 price target on the stock. Bank of America assumed coverage on GE HealthCare Technologies in a research report on Monday, July 31st. They issued a “neutral” rating and a $82.00 price target on the stock. Morgan Stanley assumed coverage on GE HealthCare Technologies in a research report on Tuesday, June 27th. They issued an “equal weight” rating on the stock. Finally, Wells Fargo & Company assumed coverage on GE HealthCare Technologies in a research report on Wednesday, August 16th. They issued an “overweight” rating and a $90.00 price target on the stock. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $89.25.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally.